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Original article
Effect of intraperitoneal chemotherapy concentration
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Background: Selected patients with colorectal peritoneal metastases are treated with cytoreductive
surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The concentration of intraperi-
toneal chemotherapy reflects the administered dose and perfusate volume. The aim of this study was to
calculate intraperitoneal chemotherapy concentration during HIPEC and see whether this was related to
clinical outcomes.
Methods: An observational multicentre study included consecutive patients with colorectal peritoneal
metastases who were treated with CRS–HIPEC between 2010 and 2018 at three Dutch centres. Data
were retrieved from prospectively developed databases. Chemotherapy dose and total circulating volumes
of carrier solution were used to calculate chemotherapy concentrations. Postoperative complications,
disease-free and overall survival were correlated with intraoperative chemotherapy concentrations.
Univariable and multivariable logistic regression, Cox regression and survival analyses were performed.
Results: Of 320 patients, 220 received intraperitoneal mitomycin C (MMC) and 100 received oxaliplatin.
Median perfusate volume for HIPEC was 5⋅0 (range 0⋅7–10⋅0) litres. Median intraperitoneal chemother-
apy concentration was 13⋅3 (range 7⋅0–76⋅0) mg/l for MMC and 156⋅0 (91⋅9–377⋅6) mg/l in patients
treated with oxaliplatin. Grade III or higher complications occurred in 75 patients (23⋅4 per cent). Median
overall survival was 36⋅9 (i.q.r. 19⋅5–62⋅9) months. Intraperitoneal chemotherapy concentrations were not
associated with postoperative complications or survival.
Conclusion: CRS–HIPEC was performed with a wide variation in intraperitoneal chemotherapy con-
centrations that were not associated with complications or survival.
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Introduction
Selected patients with colorectal peritoneal metastases
are currently offered cytoreductive surgery com-
bined with hyperthermic intraperitoneal chemotherapy
(CRS–HIPEC). This results in improved median survival
compared with systemic chemotherapy1–3.
Successful treatment of colorectal peritoneal metastases
with CRS–HIPEC depends on several factors, including
optimal patient selection and completeness of CRS4,5. The
concentration of the active agent used for intraperitoneal
chemotherapy may also be important. The most widely
used intraperitoneal chemotherapeutic drugs are mito-
mycin C (MMC), oxaliplatin and irinotecan6, any of which
may be used with systemic therapies. Existing studies7,8
have shown major differences regarding the intraperitoneal
temperature, duration and perfusate volume. Intraperi-
toneal chemotherapy dosage is usually based on body sur-
face area (BSA). Carrier solution volume has, however,
received little attention. In the Netherlands, the carrier
solution volume is not standardized. Volumes used reflect
the remaining abdominal capacity after CRS. This itself is
influenced by variations in tumour load, visceral resections
and muscle tone of the abdominal wall. These variations
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inevitably result in different intraperitoneal chemotherapy
concentrations being used in patients with similar BSA
receiving similar drug doses.
Complication rates in patients treated with intraperi-
toneal MMC or oxaliplatin have been shown to be similar9,
but the effects of higher concentrations of intraperitoneal
chemotherapy have not been evaluated to see whether
there is a relationship with increased occurrence of adverse
events, or whether lower concentrations might be asso-
ciated with worse survival. The aim of this study was
to measure final intraperitoneal chemotherapy concentra-
tions during the HIPEC and to evaluate their impact on
complications and survival.
Methods
This cohort study was performed in three tertiary insti-
tutes in the Netherlands: Radboud University Medical
Centre, the Netherlands Cancer Institute (NCI) and Uni-
versity Medical Centre Groningen. Consecutive patients
with colorectal peritoneal metastases who underwent pri-
mary CRS–HIPEC between 2010 and 2018 were eligible.
Patients with appendiceal neoplasms other than adeno-
carcinoma and who were undergoing second and/or third
HIPEC procedures were excluded. Prospectively devel-
oped databases of all patients treated with CRS–HIPEC
were in place at all three centres. Before surgery, all patients
were discussed in a multidisciplinary team meeting, involv-
ing surgeons, medical oncologists, radiologists, gastroen-
terologists and pathologists.
This study was performed in accordance with local med-
ical ethical guidelines and collection of coded data was
approved by the local medical ethical committee of Rad-
boud University Medical Centre.
Data collection and outcomes
Patient and treatment characteristics, along with opera-
tive details, details on the HIPEC procedure, histology
findings, postoperative complications, disease-free sur-
vival (DFS) and overall survival (OS) were recorded. The
intraperitoneal chemotherapy concentration was calcu-
lated by dividing the administered chemotherapy dose by
the total volume of instilled carrier solution.
Postoperative complications were scored according to
the National Cancer Institute’s Common Terminology
Criteria of Adverse Events (v4.03)10 or the Clavien–Dindo
classification11. DFS and OS were defined as the time from
the date of operation to the date of disease recurrence or
death, date of censoring or end of follow-up. Patients were
excluded if they had surgery less than 6 months before data
analyses.
To assess the impact of intraperitoneal chemotherapy
concentrations on secondary outcomes, patients were clas-
sified in three groups; for both MMC and oxaliplatin the
different groups were based on the lowest 25 per cent, mid-
dle 50 per cent and highest 25 per cent intraperitoneal
chemotherapy concentrations.
The Peritoneal Cancer Index (PCI)12 and Dutch Region
Count13 were combined to create patient groups based
on volume of disease categorized as limited, moderate or
extensive peritoneal metastases. Patients with a PCI below
7 or a region count of 0–2 were placed in the lowest
category. The moderate group consists of patients with a
PCI of 7–20 or a region count of 3–5. Lastly, patients with
a PCI above 20 or region count of 6–7 were placed in the
group with extensive peritoneal metastases.
Surgical procedure
During explorative laparotomy, the extent of peritoneal
disease was scored according to the PCI12 and/or the Dutch
Region Count13. Generally, when the PCI was 20 or less
and/or the Region Count was 5 or less, the surgeons
pursued complete cytoreduction. Completeness of cytore-
duction score or the R score was used: CC0/R1 resec-
tion represents no visible macroscopic tumour nodules
after cytoreduction; CC1/R2a resection represents tumour
nodules smaller than 2.5 mm CC2/R2b resection repre-
sents tumour nodules of 2⋅5–25 mm; and CC3 represents
tumour nodules greater than 25 mm14.
After exploratory laparotomy and CRS, HIPEC was
performed, as described in detail elsewhere2. The open
‘coliseum technique’ was used to create a basin in the
abdominal cavity. Two to four inflow catheters and two out-
flow catheters were used. The abdominal cavity was filled
with a carrier solution (Dianeal® PD1.36; Baxter, Utrecht,
the Netherlands) in the NCI, 5 per cent dextrose (Bax-
ter) in Radboud University Medical Centre and Univer-
sity Medical Centre Groningen for oxaliplatin and 0⋅9 per
cent sodium chloride for MMC until all peritoneal sur-
faces had been submerged. Chemotherapeutic drugs were
added when the optimal temperature was steadily reached,
as described below. Dosage of MMC or oxaliplatin was
based on BSA, with a maximum BSA of 2 m2 for MMC.
Patients received MMC or oxaliplatin according to institu-
tional practice. In March 2014, Radboud University Medi-
cal Centre and the NCI switched standard MMC protocols
to oxaliplatin.
For HIPEC with MMC, 35 mg/m2 heated to 41–43∘C
was administered for 90 min. Half of the total MMC dose
was given at the start of the HIPEC procedure, a further
one-quarter 30 min after the start and the last one-quarter
© 2020 The Authors. www.bjsopen.com BJS Open 2020; 4: 293–300
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Table 1 Patient, tumour and treatment characteristics
All patients (n = 320) MMC (n = 220) Oxaliplatin (n = 100) P†
Patient characteristics
Age (years)* 59⋅7±13⋅2 58⋅5±14⋅0 62⋅4±10⋅7 0⋅161‡
Sex ratio (M : F) 148 : 172 102 : 118 46 : 54 0⋅952
ASA fitness grade 0⋅655
≤ II 291 (90⋅9) 199 (90⋅5) 92 (92⋅0)
> II 29 (9⋅1) 21 (9⋅5) 8 (8⋅0)
Co-morbidity 0⋅069
Cardiac 51 (15⋅9) 36 (16⋅4) 15 (15⋅0)
Vascular 58 (18⋅1) 46 (20⋅9) 12 (12⋅0)
Pulmonary 17 (5⋅3) 15 (6⋅8) 2 (2⋅0)
Diabetic 28 (8⋅8) 20 (9⋅1) 8 (8⋅0)
Tumour characteristics
pT category 0⋅114
≤pT3 128 (40⋅0) 95 (43⋅2) 33 (33⋅0)
pT4 158 (49⋅4) 100 (45⋅5) 58 (58⋅0)
pTx 34 (10⋅6) 25 (11⋅4) 9 (9⋅0)
pN category 0⋅036
pN0 69 (21⋅6) 48 (21⋅8) 21 (21⋅0)
pN1 100 (31⋅3) 71 (32⋅3) 29 (29⋅0)
pN2 123 (38⋅4) 76 (34⋅5) 47 (47⋅0)
pNx 28 (8⋅8) 25 (11⋅4) 3 (3⋅0)
Time of diagnosis of peritoneal metastasis 0⋅128
Synchronous 169 (52⋅8) 115 (52⋅3) 54 (54⋅0)
Metachronous 143 (44⋅7) 102 (46⋅4) 41 (41⋅0)
Unknown 8 (2⋅5) 3 (1⋅4) 5 (5⋅0)
Tumour location 0⋅184
Appendiceal adenocarcinoma 30 (9⋅4) 25 (11⋅4) 5 (5⋅0)
Colon 253 (79⋅1) 171 (77⋅7) 82 (82⋅0)
Rectum 37 (11⋅6) 24 (10⋅9) 13 (13⋅0)
Differentiation grade 0⋅003
Good or moderate 184 (57⋅5) 124 (56⋅4) 60 (60⋅0)
Poor 87 (27⋅2) 67 (30⋅5) 20 (20⋅0)
Unknown 49 (15⋅3) 29 (13⋅2) 20 (20⋅0)
Histology 0⋅020
Adenocarcinoma 188 (58⋅8) 117 (53⋅2) 71 (71⋅0)
Mucinous adenocarcinoma 75 (23⋅4) 61 (27⋅7) 14 (14⋅0)
SRCC 27 (8⋅4) 20 (9⋅1) 7 (7⋅0)
Unknown 30 (9⋅4) 22 (10⋅0) 8 (8⋅0)
Treatment characteristics
Extent of peritoneal metastasis 0⋅002
Limited 115 (35⋅9) 69 (31⋅4) 46 (46⋅0)
Moderate 143 (44⋅7) 99 (45⋅0) 44 (44⋅0)
Extensive 21 (6⋅6) 14 (6⋅4) 7 (7⋅0)
Unknown 41 (12⋅8) 38 (17⋅3) 3 (3⋅0)
Completeness of cytoreduction 0⋅397
R1 303 (94⋅7) 207 (94⋅1) 96 (96⋅0)
R2a 13 (4⋅1) 9 (4⋅1) 4 (4⋅0)
R2b 4 (1⋅3) 4 (1⋅8) 0 (0)
Clavien–Dindo complication grade n = 319 n = 219 n = 100 0⋅013
No serious adverse events 133 (41⋅7) 84 (38⋅4) 49 (49⋅0)
I–II 105 (32⋅9) 82 (37⋅4) 23 (23⋅0)
III–IV 74 (23⋅2) 46 (21⋅0) 28 (28⋅0)
V 7 (2⋅2) 7 (3⋅2) 0 (0)
Unknown 1 (0⋅3) 1 (0⋅3) 0(0)
Values in parentheses are percentages unless indicate otherwise; *values are mean(s.d.). MMC, mitomycin C; SRCC, signet ring cell carcinoma. †χ2 or
Fisher’s exact test, except ‡Student’s t test.
© 2020 The Authors. www.bjsopen.com BJS Open 2020; 4: 293–300
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of the total dose 60 min after the start. When oxaliplatin
was used before HIPEC, intravenous leucovorin 20 mg/m2
was administered followed by 5-fluorouracil 400 mg/m2.
Thereafter, the carrier solution was heated to 43∘C with
oxaliplatin 460 mg/m2 added and perfused for 30 min. All
patients were admitted to the ICU after surgery.
Follow-up
Biannual CT of the chest and abdomen was performed
in the first 5 years after CRS–HIPEC, along with mea-
surement of the serum tumour markers carcinoembryonic
antigen, carbohydrate antigen (CA) 125 and CA-19-9. In
the NCI, CT and serum tumour markers were performed
annually after the first 2 years of biannual follow-up. Recur-
rences and OS were registered.
Statistical analysis
Mean and median values were analysed with Student’s t test
or the Mann–Whitney U test depending on distribution.
Categorical variables were cross-tabulated and significant
differences identified using Fisher’s exact test or the χ2 test
as appropriate. Kaplan–Meier estimates of survival were
calculated. OS was compared between groups with dif-
ferent intraperitoneal chemotherapy concentrations, using
the log rank test. All tests performed were two-sided, and
P < 0⋅050 was considered statistically significant. Statisti-
cal analyses were performed with the SPSS® version 22.0
(IBM, Armonk, New York, USA).
Multivariable Cox regression analyses were performed
with variables that were significant in univariable analysis
or considered clinically relevant (tumour differentiation, N
category, completeness of cytoreduction score and extent of
disease).
Results
A total of 320 patients underwent CRS–HIPEC and were
included. Of these, 220 received intraperitoneal MMC and
100 received intraperitoneal oxaliplatin. Median follow-up
was 22⋅4 (range 0⋅1–122⋅6) months. Baseline characteris-
tics of the two groups are described in Table 1.
Median BSA was 1⋅9 (range 1⋅3–2⋅5) m2. Median total
dose of chemotherapy was 66⋅9 (range 35⋅0–89⋅1) mg
for MMC and 877⋅0 (572⋅4–1060⋅0) mg for oxali-
platin. Median carrier solution volume was 5⋅0 (range
0⋅7–10⋅0) litres (Fig. 1a). Median calculated intraperi-
toneal chemotherapy concentration was 13⋅3 (range
7⋅0–76⋅0) mg/l for MMC and 156⋅0 (91⋅9–377⋅6) mg/l
for oxaliplatin (Fig. 1b,c).
Fig. 1 Details of intra-abdominal volumes and body surface














































































a Scatterplot of intra-abdominal volume and body surface area (BSA).
Note the variation in intra-abdominal volume at the same BSA. b,c
Box-and-whisker plots of calculated concentrations of mitomycin C
(MMC) and oxaliplatin. Median values, interquartile ranges and ranges
(excluding outliers) are denoted by horizontal bars, boxes and error bars
respectively.
Table 2 Postoperative complications and their relation to the




Calculated concentration n 0–II III–IV P*
MMC (mg/l) 0⋅492
Lower quartile (7⋅0–11⋅2) 55 45 (82) 10 (18)
Mid range (11⋅2–15⋅4) 110 81 (73⋅6) 29 (26⋅4)
Upper quartile (15⋅4–76⋅0) 55 41 (75) 14 (25)
Oxaliplatin (mg/l) 0⋅575
Lower quartile (91⋅9–131⋅1) 25 16 (64) 9 (36)
Mid range (131⋅3–184⋅0) 49 37 (76) 12 (24)
Upper quartile (184⋅0–377⋅6) 26 19 (73) 7 (27)
Values in parentheses are percentages. MMC, mitomycin C. *χ2 or Fisher’s
exact test.
© 2020 The Authors. www.bjsopen.com BJS Open 2020; 4: 293–300
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a,c Overall (OS) and disease-free (DFS) survival in patients receiving mitomycin C (MMC) and b,d OS and DFS in patients receiving oxaliplatin, according
to lower quartile, mid range and upper quartile intraperitoneal chemotherapy concentration. a P = 0⋅671, b P = 0⋅703, c P = 0⋅170, d P = 0⋅624 (log rank
test).
Grade III and above complications occurred in 81 of 320
patients (25⋅3 per cent) (Table 1). Median OS was 36⋅9 (i.q.r.
19⋅5–62⋅9) months for the overall cohort (36⋅9 (range
0⋅1–122⋅6) months for MMC and 29⋅5 (0⋅6–42⋅8) months
for oxaliplatin; P = 0⋅516). Median DFS was 12⋅9 (range
0⋅1–107⋅4) and 13⋅1 (0⋅6–42⋅8) months in the MMC and
oxaliplatin group respectively.
Effects of concentration of intraperitoneal
chemotherapy
Table 2 summarizes the different concentrations of MMC
and oxaliplatin in the three stratified chemotherapy con-
centration groups and the association with postoperative
surgical complications. Complication rates and grades
were not significantly different between patients who
received low, mid or high concentrations of intraperi-
toneal chemotherapy in either group (MMC: P = 0⋅492;
oxaliplatin: P = 0⋅575).
Fig. 2 illustrates OS and DFS for MMC and oxaliplatin
per stratified chemotherapy concentration group (lower
quartile, mid range and upper quartile). No significant
association was observed between any of the concentration
groups and OS or DFS.
Multivariable Cox regression analysis identified pN
category, extent of peritoneal metastases and completeness
of cytoreduction as independent prognostic factors for
OS (Fig. 3). The calculated circulating chemotherapy
© 2020 The Authors. www.bjsopen.com BJS Open 2020; 4: 293–300
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a,c Overall (OS) and disease-free (DFS) survival in patients receiving mitomycin C (MMC) and b,d OS and DFS in patients receiving oxaliplatin. Hazard
ratios are shown with 95 per cent confidence intervals. PM, peritoneal metastases.
concentration during HIPEC was not associated with
adverse effects on survival or disease recurrence.
Discussion
This study has shown wide variation in intraperitoneal
carrier solution volumes in patients with colorectal peri-
toneal metastases treated with CRS–HIPEC in three ter-
tiary Dutch centres. Variations in carrier solution volume
resulted in different calculated intraperitoneal chemother-
apy concentrations for both MMC and oxaliplatin. Calcu-
lated intraperitoneal chemotherapy concentrations varied
tenfold and fourfold for MMC and oxaliplatin respectively.
Postoperative complication, DFS and OS rates were not
affected by differences in chemotherapy concentrations,
regardless of HIPEC chemotherapy type.
The recently completed PRODIGE 7 trial15 (NCT007
69405), which compared systemic chemotherapy combined
with CRS–HIPEC (oxaliplatin) or systemic chemother-
apy with CRS alone, did not find a significant bene-
fit for oxaliplatin-based HIPEC over CRS alone16–18. In
both groups, median survival was more than 40 months.
Interpretation of the results from the PRODIGE 7 study
remains difficult because the additional effect of systemic
chemotherapy remains to be proven by the CAIRO6
study (NCT02758951). Other recent studies – the Dutch
COLOPEC trial (NCT02231086)19 and the French PRO-
PHYLOCHIP trial (NCT01226394)20 – investigated dif-
ferent aspects of HIPEC treatment, but still failed to
resolve the relative contributions made by cytoreductive
surgery, hyperthermia, intraperitoneal chemotherapy and
perioperative systemic therapy on survival.
The present study aimed to address the potential impact
of the intraperitoneal concentration of the chemothera-
peutic agent. The findings suggest that concentration dif-
ferences, within the limits identified, play a minor role in
outcome after CRS–HIPEC.
Theoretically, a low concentration might reduce the effi-
cacy of the agent, but no relationship existed between con-
centration and patient survival. Nor was there any rela-
tionship between complications and different calculated
chemotherapy concentrations. Several explanations are
© 2020 The Authors. www.bjsopen.com BJS Open 2020; 4: 293–300
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possible for the lack of association between concentration
and survival. If the lowest chemotherapy concentration was
above a threshold required to inhibit cell proliferation and
cell cycle progression in tumour cells within the given
perfusion period, higher concentrations might not impact
on survival. The intraperitoneal chemotherapy, as admin-
istered in these protocols, might not have added benefit
above the other components of CRS–HIPEC, as suggested
by the PRODIGE 7 trial. Variable intraperitoneal volumes
may also have had a confounding effect21. A recent study22
with patient-derived organoids did, however, find that cur-
rently used concentrations might be insufficient for com-
plete eradication of all malignant cells. This merits further
investigation, as drug concentrations may be critical as new
agents are introduced.
Worldwide treatment variation in CRS–HIPEC regi-
mens is well recognized, and standardization can improve
outcomes23. The American Society of Peritoneal Surface
Malignancies has proposed a standardized MMC protocol
based on consensus8. Despite a willingness to standardize,
differences in protocols still exist, as shown in two recent
systematic reviews6,24. In the Netherlands there is no stan-
dardization for the intraperitoneal carrier solution volume.
The total carrier solution volume is based on the intraperi-
toneal volume, whereas the total chemotherapeutic dose
is based on BSA, inevitably resulting in wide variations in
concentration.
Although drug concentration was not identified as a
significant risk factor influencing survival or complica-
tions, optimization of chemotherapy concentrations might
contribute to standardized treatments, particularly as new
agents are introduced.
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